Myoderm Opens Brand New UK Clinical Distribution Facility

Published: Feb 28, 2017

NORRISTOWN, Pa., Feb. 28, 2017 /PRNewswire/ -- Myoderm, a global leader in clinical trial supply, is excited to announce the opening of their new UK headquarters. This clinical storage and distribution facility was strategically developed in response to ongoing challenges in the clinical trial industry, growing needs of customers around the world, as well as Myoderm's continually expanding global footprint.

Serving as the new home to the UK team, the state-of-the-art, fully licensed warehouse is designed for the storage and distribution of commercial drugs in ambient, refrigerated, and controlled environments. Dedicated rooms within the warehouse will facilitate secondary labeling, as well as site and patient kit assembly. These features will complement and enhance the broad range of services Myoderm provides to their clients.

Michael Cohen, Managing Director, remarks, "This has been in the works for a long time, and we can't wait to utilize it to serve clinical trials around the world. Having warehouses in both the UK and US will allow us to provide even better solutions and add further value to both our clients and partners."

Matt Grace, Director, International Supply Services, adds, "We are extremely proud of our new UK headquarters. It's truly an impressive facility, and we're excited about the opportunities it presents for both our clients and our company."

About Myoderm

Myoderm is a specialist in global clinical trial supply, with deep expertise in sourcing, management, and labeling of commercial drugs and supplies. Their ingenuity, strategic thinking, and obsession with providing the most efficient, effective, and seamless supply solutions is why top pharmaceutical companies, biotech companies, CROs, and clinical trial packagers around the world rely on Myoderm.

Media Contact
Maryanne Walsh
Phone: +1 610 233 3311

Related Links



This content was issued through the press release distribution service at For more info visit:

To view the original version on PR Newswire, visit:

SOURCE Myoderm

Back to news